MK0249

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Alzheimer's DiseaseAttention-Deficit/Hyperactivity Disorder (ADHD)Paranoid Schizophrenia

Phase 2

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

CompletedNCT00420420

Merck Sharp & Dohme LLCAlzheimer's Disease

Start: 2006-11-30End: 2008-08-31Updated: 2015-02-12

A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)

CompletedNCT00475735

Merck Sharp & Dohme LLCAttention-Deficit/Hyperactivity Disorder (ADHD)

Start: 2007-07-31End: 2008-04-30Updated: 2015-07-28

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

CompletedNCT00506077

Merck Sharp & Dohme LLCParanoid Schizophrenia

Start: 2007-12-31End: 2008-10-31Updated: 2015-08-03

Related Papers

Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.

2013-03-2237 citations

Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.

2012-07-0129 citations

Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.

2012-05-0132 citations